MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
-0.37 (-2.10%)
At close: 4:00PM EST

17.24 0.00 (0.00%)
After hours: 5:26PM EST

Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous close17.61
Bid17.22 x 1300
Ask17.29 x 2200
Day's range17.00 - 17.57
52-week range16.63 - 36.94
Avg. volume5,756,807
Market cap8.898B
Beta (3Y monthly)1.76
PE ratio (TTM)191.56
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date2007-06-27
1y target estN/A
Press releases
  • Business Wire

    Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (NASDAQ: MYL) resolving patent litigations brought in response to Mylan’s abbreviated new drug applications (ANDAs) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents. The settlement with Mylan is the third patent infringement settlement the companies have reached with respect to LINZESS.

  • We're sorry, but this is all we were able to find on this topic.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more